Antibody–Drug Conjugates: In Search of Partners of Choice

Researchers review various antibody–drug conjugate( ADC)-based treatment combinations, and highlight that the most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment, without unacceptable overlapping toxicities.